JSAM
KYMR icon

J. Safra Asset Management’s Kymera Therapeutics KYMR Stock Holding History

J. Safra Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.45K Sell
65
-14
-18% -$1.2K ﹤0.01% 436
2026
Q1 		$6.58K Buy
+79
New +$6.26K ﹤0.01% 424

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

J. Safra Asset Management's KYMR Position: Q2 2026 in Review

J. Safra Asset Management reduced its Kymera Therapeutics (KYMR) stake by 18% in Q2 2026, selling an estimated $1.2K and leaving 65 shares worth $7.45K. The position accounts for ﹤0.01% of the portfolio, ranked #436.

J. Safra Asset Management first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • J. Safra Asset Management held 65 shares of Kymera Therapeutics worth $7.45K as of Q2 2026.
  • J. Safra Asset Management sold 14 Kymera Therapeutics shares in Q2 2026, an estimated $1.2K.
  • Kymera Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #436 holding.
  • J. Safra Asset Management first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.